12:00 AM
Aug 22, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Lucassin terlipressin: Phase III started

Mallinckrodt began the double-blind, placebo-controlled, North American Phase III CONFIRM trial to evaluate 1 mg IV Lucassin every 6 hours in about 300 patients. Lucassin is approved outside the U.S. and Canada to treat Type I HRS.

Mallinckrodt gained North American...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >